PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
5.86%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
-142.73%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-120.58%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-120.58%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
10.21%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
10.21%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
9.39%
OCF growth of 9.39% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
9.37%
FCF growth of 9.37% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-5186.83%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-34380.15%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-67208.18%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-8163.79%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-121.82%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
31995.75%
Equity/share CAGR of 31995.75% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
9371.92%
5Y equity/share CAGR of 9371.92% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
10880.98%
3Y equity/share CAGR of 10880.98% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Asset growth of 31.29% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
28.45%
BV/share growth of 28.45% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-51.38%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-5.21%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-6.73%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.